Retrospective analysis of outcome and toxicity after postoperative radiotherapy in patients with squamous cell carcinoma of the lip.
Head and neck cancer
extracapsular spread
local control
squamous cell carcinoma
Journal
Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
pubmed:
2
3
2021
medline:
7
4
2022
entrez:
1
3
2021
Statut:
ppublish
Résumé
Carcinomas of the lips are a relatively common malignancy of the head and neck region, accounting for roughly one quarter of all oral cavity cancers. Compared to other oral cancer sites, this location has a favorable prognosis, with 5-year survival rates between 85% and 95%. This study summarizes our institutional experience in utilizing postoperative radiation for patients with squamous cell carcinoma of the upper and/or lower lip following incomplete surgical resection or positive lymph node involvement with extracapsular extension. We retrospectively reviewed the medical records of all patients at the University Hospital of Heidelberg between 2005 and 2018 treated with postoperative radiotherapy of the upper and lower lip. Nineteen patients were identified with a median age at diagnosis of 67 years (range, 41-95 years), with 58% male and 42% female patients. Fourteen patients (73.7%) underwent neck dissection, with 5 (35.7%) found to have extracapsular extension (ECE) and positive resection margin (R1/2), 2 (14.3%) only ECE, and 7 (50.0%) with only R1/2. All patients received a median cumulative dose of 66.0 Gy (range, 60.0-70.0 Gy) in a median of 2.0 Gy per fraction (range, 1.8-2.2 Gy). Median follow-up was 5.2 years. The median progression-free survival (PFS) was 3.9 years (range, 0.2-12.4 years), local disease-free survival (LDFS) was 4 years (range, 1-12 years) and overall survival (OS) was 5.2 years (range, 0.2-12.4 years). The 5-year Kaplan-Meier estimates for OS, PFS, and LDFS were 61.4%, 85.7%, and 100.0%, respectively. At last follow-up, 13 patients (68.4%) were still alive. Although no patient developed locoregional relapse, two patients developed distant relapse at a median of 15 months after radiotherapy. There was a statistically significant improvement in OS in patients treated with higher radiotherapy doses (>60.0 Gy, Our results demonstrate excellent local control and OS with acceptable toxicity when utilizing postoperative radiotherapy in patients with squamous cell carcinoma of the upper and lower lip, despite unfavorable characteristics (advanced T or N stage and/or ECE).
Sections du résumé
BACKGROUND
BACKGROUND
Carcinomas of the lips are a relatively common malignancy of the head and neck region, accounting for roughly one quarter of all oral cavity cancers. Compared to other oral cancer sites, this location has a favorable prognosis, with 5-year survival rates between 85% and 95%. This study summarizes our institutional experience in utilizing postoperative radiation for patients with squamous cell carcinoma of the upper and/or lower lip following incomplete surgical resection or positive lymph node involvement with extracapsular extension.
METHODS
METHODS
We retrospectively reviewed the medical records of all patients at the University Hospital of Heidelberg between 2005 and 2018 treated with postoperative radiotherapy of the upper and lower lip. Nineteen patients were identified with a median age at diagnosis of 67 years (range, 41-95 years), with 58% male and 42% female patients. Fourteen patients (73.7%) underwent neck dissection, with 5 (35.7%) found to have extracapsular extension (ECE) and positive resection margin (R1/2), 2 (14.3%) only ECE, and 7 (50.0%) with only R1/2. All patients received a median cumulative dose of 66.0 Gy (range, 60.0-70.0 Gy) in a median of 2.0 Gy per fraction (range, 1.8-2.2 Gy).
RESULTS
RESULTS
Median follow-up was 5.2 years. The median progression-free survival (PFS) was 3.9 years (range, 0.2-12.4 years), local disease-free survival (LDFS) was 4 years (range, 1-12 years) and overall survival (OS) was 5.2 years (range, 0.2-12.4 years). The 5-year Kaplan-Meier estimates for OS, PFS, and LDFS were 61.4%, 85.7%, and 100.0%, respectively. At last follow-up, 13 patients (68.4%) were still alive. Although no patient developed locoregional relapse, two patients developed distant relapse at a median of 15 months after radiotherapy. There was a statistically significant improvement in OS in patients treated with higher radiotherapy doses (>60.0 Gy,
CONCLUSION
CONCLUSIONS
Our results demonstrate excellent local control and OS with acceptable toxicity when utilizing postoperative radiotherapy in patients with squamous cell carcinoma of the upper and lower lip, despite unfavorable characteristics (advanced T or N stage and/or ECE).
Identifiants
pubmed: 33641520
doi: 10.1177/0300891621996805
pmc: PMC8984927
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-133Références
Oral Oncol. 2004 Feb;40(2):223-7
pubmed: 14693248
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Am J Surg. 1990 Oct;160(4):405-9
pubmed: 2221244
J Plast Reconstr Aesthet Surg. 2010 Dec;63(12):2040-5
pubmed: 20129833
Int J Oral Maxillofac Surg. 1998 Jun;27(3):199-203
pubmed: 9662013
Otolaryngol Head Neck Surg. 2000 Jan;122(1):139-42
pubmed: 10629501
Radiother Oncol. 2011 Jul;100(1):33-40
pubmed: 21684027
J Craniofac Surg. 2009 Jan;20(1):248-52
pubmed: 19165039
J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8
pubmed: 1430364
J Otolaryngol. 1984 Feb;13(1):32-6
pubmed: 6716547
Am J Clin Oncol. 2011 Aug;34(4):356-61
pubmed: 21633289
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518108
J Clin Oncol. 2015 Oct 10;33(29):3269-76
pubmed: 26351335
Lancet Oncol. 2001 Sep;2(9):533-43
pubmed: 11905707
Surg Gynecol Obstet. 1985 Jan;160(1):37-41
pubmed: 3880619
Am J Otolaryngol. 1992 Nov-Dec;13(6):363-5
pubmed: 1443392
Otolaryngol Head Neck Surg. 1995 Nov;113(5):589-96
pubmed: 7478649
Aust Dent J. 2009 Jun;54(2):130-5
pubmed: 19473154
Am J Surg. 1979 Oct;138(4):600-3
pubmed: 484790
Curr Opin Oncol. 2009 May;21(3):194-200
pubmed: 19363341
Cochrane Database Syst Rev. 2011 Apr 13;(4):CD006386
pubmed: 21491393
Hum Pathol. 1986 Apr;17(4):346-54
pubmed: 3957335
Med Oral Patol Oral Cir Bucal. 2018 Jan 1;23(1):e23-e29
pubmed: 29274153
Br J Dermatol. 2010 May;162(5):1103-9
pubmed: 20163415
Oral Oncol. 2009 Apr-May;45(4-5):394-401
pubmed: 18674952
Australas Radiol. 2001 May;45(2):195-9
pubmed: 11380363
CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29
pubmed: 9449931
Head Neck. 1989 May-Jun;11(3):264-8
pubmed: 2722504
Dent Update. 2006 Nov;33(9):538-9, 542-5
pubmed: 17176740
Aust N Z J Surg. 2000 May;70(5):358-61
pubmed: 10830600
ANZ J Surg. 2003 Aug;73(8):621-5
pubmed: 12887533
Otolaryngol Clin North Am. 1993 Apr;26(2):265-77
pubmed: 8460042
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Mar;109(3):e74-9
pubmed: 20219590
Head Neck. 2013 Oct;35(10):1426-30
pubmed: 22965889